Sharp tomosynthesis technology may catch breast cancer earlier

Share this article:

A technology that provides three-dimensional (3D) imaging of the breast may represent the next generation in breast cancer detection.

Similar to computed tomography, tomosynthesis acquires multiple, low-dose images at different angles. The images are then used to produce a series of 1-mm-thick slices that can be viewed as a 3D reconstruction of the breast. Features that might be obscured in a traditional two-dimensional mammogram due to overlapping breast anatomy that may mimic or mask a tumor can be easily identified and characterized in the tomosynthesis-produced images. This can reduce the number of false-positive or false-negative findings.

The tomosynthesis unit resembles earlier mammography machines, and the amount of breast compression required is identical to that required for conventional mammography.

University Hospitals (UH) Case Medical Center (Cleveland, Ohio) was involved with early studies of the tomosynthesis technology, and has announced that its patients are among the first in the nation to be offered the system.

“This revolutionary new technology provides exceptionally sharp images and is an important new tool in our arsenal to detect breast cancer early, when it is treatable,” explained Donna Plecha, MD, director of breast imaging at the medical center, in a statement issued by UH Case Medical Center.

Share this article:
You must be a registered member of ONA to post a comment.

Next Article in Web Exclusives

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.